

HOSTED BY



Contents lists available at ScienceDirect

Journal of King Saud University – Science

journal homepage: [www.sciencedirect.com](http://www.sciencedirect.com)

Original article

## Exploring the impact of paracetamol on the transcriptome of *Streptococcus pneumoniae* D39



Muhammad Afzal<sup>a</sup>, Hifza Ahmed<sup>a</sup>, Muhammad Hussnain Siddique<sup>a</sup>, Saima Muzammil<sup>b</sup>, Farrukh Azeem<sup>a</sup>, Sumreen Hayat<sup>b</sup>, Sulman Shafeeq<sup>c,\*</sup>, Mohammed F. Albeshr<sup>d</sup>, Shahid Mahboob<sup>d,\*</sup>

<sup>a</sup> Department of Bioinformatics and Biotechnology, Government College University, Faisalabad 38000, Pakistan

<sup>b</sup> Department of Microbiology, Government College University, Faisalabad 38000, Pakistan

<sup>c</sup> Karolinska Institute, Stockholm, Sweden

<sup>d</sup> Department of Zoology, College of Science, King Saud University, Riyadh 11451, Saudi Arabia

### ARTICLE INFO

#### Article history:

Received 23 May 2022

Revised 17 June 2022

Accepted 13 August 2022

Available online 19 August 2022

#### Keywords:

Pneumococcus

Paracetamol

Transcriptomics

Protein-protein interaction networks

Pathway enrichment analysis

### ABSTRACT

**Introduction:** Paracetamol (acetaminophen) is a medicine used for the treatment of fever, pain, and inflammation during pneumococcal infection.

**Objectives:** To see how paracetamol affects the transcriptional profile of *Streptococcus pneumoniae* across the genome.

**Methods:** In this study, microarray analysis was performed for transcriptional profiling.

**Results:** Transcriptome data showed differential expression of several genes in *S. pneumoniae* D39 wild-type incorporated with paracetamol in the growth medium. Furthermore, these genes were categorized using Clusters of Orthologous Groups (COG) functional categorization on the basis of the suspected functions of the respective proteins. The majority of differentially expressed genes are in COG categories E (Amino acid transport and metabolism) and I (Lipid transport and metabolism). Analysis of protein-protein interaction networks exhibited compactly connected networks between fatty acid transport/biosynthesis and antibiotic biosynthesis genes. Moreover, pathways enrichment analysis revealed that fatty acid metabolism and biosynthesis genes were significantly affected under the criteria we've established.

**Conclusion:** These results suggest the fatty acid biosynthesis and metabolism genes to be potential target of paracetamol in *S. pneumoniae* D39 wild-type.

© 2022 The Authors. Published by Elsevier B.V. on behalf of King Saud University. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

## 1. Introduction

An opportunistic pathogen of humans, *Streptococcus pneumoniae*, inhabits the mucosa of nasal portions and causes sinusitis, otitis media, sepsis, meningitis and pneumonia which results about a million people deaths every year worldwide (O'Brien et al., 2009). Multi-resistant pneumococcal strains' emergence and dissemination has been on the rise since mainstream drugs usage worldwide (Kim et al., 2016). Generation of resistant pneu-

mococcal clones results through adaptation to drug pressures enforced although they reside within the human upper respiratory tract (Kim et al., 2016). Most pneumococcal antimicrobial resistances have basic causal factors that have been uncovered (Kim et al., 2016). The escalating rates of resistance to antibiotics to all currently available treatments, along with an almost empty pharmacological pathways for new drugs, has caused a panic in drug discovery efforts around the world (Brockhurst et al., 2019). Though different drugs have shown potency against most pneumococcal infections, the existing options are limited against some pneumococcal isolates (Kim et al., 2016).

Several factors are deemed liable for the development of resistance among intrusive pneumococcal disease cases including modern drug usage (foremost risk factor) (Levine et al., 1999), age (predominantly children below 5 years of age) and pediatric serotypes (serotypes found commonly in children), hospitalization, attending day care, female gender, living in an urban area, HIV infection and immunosuppression (Levine et al., 1999). At present, >40 % of pneumococcal isolates lack significant conjugate vaccine

\* Corresponding authors.

E-mail addresses: [sulman.shafeeq@ki.se](mailto:sulman.shafeeq@ki.se) (S. Shafeeq), [mushahid@ksu.edu.sa](mailto:mushahid@ksu.edu.sa) (S. Mahboob).

Peer review under responsibility of King Saud University.



Production and hosting by Elsevier

<https://doi.org/10.1016/j.jksus.2022.102282>

1018-3647/© 2022 The Authors. Published by Elsevier B.V. on behalf of King Saud University.

This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

coverage and are penicillin resistant in several countries (Torné et al., 2014). Paracetamol is deemed as the first-line remedy for an acute sore throat. Nonetheless, in primary care, antibiotics are still normally prescribed as first-line treatment for sore throat. Therefore, we believe that it would be very interesting to give a try to a less-problematic and routinely used medication paracetamol (acetaminophen/APAP) and investigate the response of pneumococcus to paracetamol at molecular level. Moreover, paracetamol has been shown to enhance biofilm formation in human pathogen *Staphylococcus aureus*. This research elucidates the impact of paracetamol on the whole transcriptome of pneumococcus and highlights the putative targets of paracetamol in pneumococcus by differential network analysis and pathway enrichment analysis.

## 2. Methods

### 2.1. Bacterial strains and growth experiments

*S. pneumoniae* D39 wild-type strain was used for our research. Growth of *S. pneumoniae* D39 was performed as mentioned before (Afzal et al., 2015). *S. pneumoniae* from  $-80^{\circ}\text{C}$  stocks were first plated on blood agar plates overnight. Next day, bacteria were taken from the blood agar plates and inoculated in GM17 (0.5 % glucose + M17) and grown overnight. Fresh cultures from the overnight grown bacteria were used for our experiments.

### 2.2. RNA extraction, cDNA preparation and hybridization

Wild-type *S. pneumoniae* D39 was grown in chemically defined media (CDM) (in replicates) with 0 and 5 mM paracetamol were used for microarrays analysis. Paracetamol was purchased from Sigma Aldrich. For RNA isolation, cells in their corresponding mid-exponential phase (grown for about 6–7 h) were harvested. The extraction of RNA and preparation of cDNA was executed as elucidated before (Afzal et al., 2015). All other aspects of the microarray experiment were carried out as depicted earlier (Afzal et al., 2015).

### 2.3. Microarray data analysis

The microarray acquisition and analysis software, GenePix<sup>®</sup> Pro 6, was utilized to perform a pre-analysis on spotted microarray slides. The data was then normalized and processed using the Microprep software program, which was developed in-house (van Hijum et al., 2003). Statistical analysis were executed as depicted previously (van Hijum et al., 2005). Cyber-T integration of a variant of *t*-test was performed (<https://bioinformatics.biol.rug.nl/cybert/index.shtml>) and FDRs (False Discovery Rates) were measured as mentioned before (van Hijum et al., 2003). A fold shift cut-off 1.5, FDR < 0.05 and Bayesian p-value of < 0.001 were applied to categorize differentially expressed genes. PePPER software package was utilized to perform additional computer research on the data in order to forecast regulatory networks and data mining (de Jong et al., 2012).

### 2.4. Analysis of protein–protein interaction (PPI) network

The protein–protein interaction (PPI) network was built and visualized via STRING with the default threshold of a combined score > 0.4 (Szklarczyk et al., 2017). Moreover, nodes denote biological molecules and the nodes are connected by the edges to show their interaction. The important nodes in the PPI network were identified using their connection degrees.

### 2.5. Functional enrichment analysis

Functional annotation analysis was executed using the Search Tool for the identification of associated Genes to further investigate biological processes of genes expressing in numerous ways in involvement of paracetamol (Szklarczyk et al., 2017). With p-values < 0.05, GO (Gene Ontology) and KEGG (Kyoto Encyclopedia of Genes and Genomes) pathways were considered enriched.

## 3. Results

### 3.1. Transcriptomic response of *S. Pneumoniae* to paracetamol

Paracetamol is one of the WHO's (World Health Organization) essential medicines, that are considered to be the most effective and the safest medicines required in a health system and usually used for mild to moderate pain relief (Lee, 2017). It could be used in conjunction with opioid pain medications for intense pain, such as cancer suffering and post-surgery pain (Scottish Intercollegiate Guidelines Network, 2008). In this study, we tested the exposure of the paracetamol on the whole transcriptome of wild-type of *S. pneumoniae* D39. Comparisons of microarrays of *S. pneumoniae* D39 grown in CDM with (5 mM) and without paracetamol was performed. A variety of genes/gene clusters was expressed in numerous ways in the involvement of paracetamol (Table 1). 54 genes were positively regulated during involvement of paracetamol, as opposed to negative regulation of 20 genes. Based on the proposed functions of the related proteins, these genes are additionally classified into COG functional classes (Table 2).

The expression of *glnA-glnR*, *glnPQ* and *gdhA* was downregulated in the administration of paracetamol. In the vicinity of a nitrogen source, the expression of these genes has been shown to be downregulated (Kloosterman et al., 2006). GlnR regulon genes play a role in pneumococcal pathogenesis, with *glnA* participating to blood colonization and resilience, and *glnP* crucial for lung survival and probably essential for effective transfer from the lungs to the blood (Kloosterman et al., 2006). An important iron operon *spd-1650-2* (*piuABC*) was found to be downregulated under our tested conditions. This system is among three major iron transport systems in pneumococcus and codes for an ABC transporter (Brown et al., 2002). This ABC transporter has specific roles in respiratory colonization and disease and is believed to be important for virulence in *S. pneumoniae* (Kadioglu et al., 2008).

A mannose-specific phosphotransferase system (*manLMN*) and a couple of genes (*malPQ*) programming for maltose utilization proteins were also expressed in numerous ways in the involvement of paracetamol. Maltose genes are positively regulated during involvement of paracetamol in the medium, whereas the mannose transporter genes are downregulated. Several genes were upregulated in the presence of paracetamol including a group of genes normatively encoding chaperones and heat-shock proteins and few genes participated in production and conversion of energy. Moreover, some amino acid utilization and transport genes were negatively regulated in the presence of paracetamol in the medium.

*fab* genes (genes for biosynthesis of fatty acids) were negatively regulated in involvement of paracetamol. A *fab* gene cluster is located in pneumococcal genome along with another system for synthesis of unsaturated fatty acids and enoyl-ACP reduction (Marrakchi et al., 2002). The study of the regulatory mechanisms and interactions of the *fab* genes in the involvement of paracetamol is necessary because they are important in modulating lipid homeostasis of the bacterial membrane, and are the potential candidates for new antibacterial therapies. Furthermore, changes in the expression of genes encoding for biosynthesis of fatty acid may

**Table 1**Summary of genes showing differential expression in *S. pneumoniae* D39 wild-type grown in CDM with and without 5 mM paracetamol.

| <sup>a</sup> D39 Tag (spd)  | <sup>b</sup> Function  | <sup>c</sup> Ratio |
|-----------------------------|--|--------------------|
| <b>Upregulated genes</b>    |  |                    |
| 0420                        | Formate acetyltransferase, PflB                              | 1.8                |
| 0458                        | HrcA   | 1.5                |
| 0459                        | GrpE   | 1.6                |
| 0460                        | DnaK   | 1.9                |
| 0461                        | DnaJ   | 1.5                |
| 0458                        | Heat-inducible transcription repressor HrcA                  | 1.5                |
| 0701                        | CiaR   | 1.6                |
| 0702                        | CiaH   | 1.7                |
| 0775                        | Function Unknown   | 2.4                |
| 0868                        | Protease maturation protein, putative                        | 2.0                |
| 0913                        | Hypothetical protein   | 2.0                |
| 1375                        | NADPH-dependent FMN reductase, putative                      | 1.7                |
| 1402                        | Non-heme iron-containing ferritin                            | 1.7                |
| 1439                        | Ribosomal protein S15, RpsO                                  | 1.6                |
| 1506                        | Acetyl xylan esterase, putative                              | 1.8                |
| 1834                        | Alcohol dehydrogenase, iron-containing                       | 4.2                |
| 1932                        | Maltodextrin phosphorylase, MalP                             | 1.8                |
| 1933                        | 4-alpha-glucanotransferase, MalQ                             | 1.6                |
| 1965                        | PcpA   | 1.5                |
| 2033                        | YfiA   | 1.5                |
| 2069                        | SpoJ   | 2.2                |
| <b>Down-regulated Genes</b> |  |                    |
| 0161                        | Hypothetical protein   | -1.9               |
| 0195                        | rplW   | -1.5               |
| 0197                        | rpsS   | -1.5               |
| 0262                        | Mannose/fructose/sorbose family PTS system                   | -1.5               |
| 0263                        | ManM   | -1.6               |
| 0264                        | ManL   | -1.5               |
| 0317                        | Cps2C  | -1.6               |
| 0334                        | AliA   | -2.1               |
| 0378                        | Enoyl-CoA hydratase/isomerase family protein                 | -2.0               |
| 0379                        | MarR family Transcriptional regulator                        | -1.6               |
| 0380                        | FabH   | -1.8               |
| 0381                        | AcpP   | -1.9               |
| 0382                        | FabK   | -2.2               |
| 0383                        | FabK   | -2.2               |
| 0384                        | FabK   | -1.9               |
| 0385                        | FabK   | -2.2               |
| 0386                        | AccB   | -2.3               |
| 0387                        | FabK   | -2.3               |
| 0388                        | AccC   | -2.0               |
| 0389                        | AccD   | -2.1               |
| 0390                        | AccA   | -1.9               |
| 0404                        | IlvB   | -2.4               |
| 0405                        | IlvN   | -2.2               |
| 0406                        | IlvC   | -2.4               |
| 0407                        | Function Unknown   | -2.3               |
| 0408                        | Function Unknown   | -2.3               |
| 0409                        | IlvA   | -2.1               |
| 0447                        | GlnR   | -2.3               |
| 0448                        | GlnA   | -1.8               |
| 0646                        | Function Unknown   | -1.6               |
| 0655                        | LivG   | -1.5               |
| 0686                        | Efflux transporter   | -1.5               |
| 0749                        | IlvE   | -1.6               |
| 0750                        | Function Unknown   | -1.9               |
| 0751                        | Function Unknown   | -1.8               |
| 0752                        | Function Unknown   | -1.7               |
| 0753                        | Pcp  | -1.5               |
| 0900                        | Asd  | -1.6               |
| 0901                        | DapA   | -1.6               |
| 1098                        | GlnP   | -1.7               |
| 1099                        | GlnQ   | -1.5               |
| 1158                        | NADP-specific glutamate dehydrogenase, GdhA                  | -1.6               |
| 1217                        | Function Unknown   | -1.6               |
| 1524                        | Transcriptional regulator, GntR family protein               | -2.1               |
| 1525                        | ABC transporter, ATP-binding protein                         | -2.4               |
| 1526                        | Function Unknown   | -3.6               |
| 1611                        | Function Unknown   | -1.6               |
| 1650                        | Iron-compound ABC transporter, permease protein              | -1.5               |
| 1651                        | Iron-compound ABC transporter, ATP-binding protein           | -1.5               |
| 1652                        | Iron-compound ABC transporter, iron-compound-binding protein | -1.6               |

(continued on next page)

**Table 1** (continued)

| <sup>a</sup> D39 Tag (spd) | <sup>b</sup> Function | <sup>c</sup> Ratio |
|----------------------------|-----------------------|--------------------|
| 1671                       | AmiA                  | -1.5               |
| 1726                       | Pneumolysin, Ply      | -1.5               |
| 1728                       | Function Unknown      | -1.6               |
| 2045                       | MreC                  | -1.6               |

<sup>a</sup> *S. pneumoniae* D39 locus tags. <sup>b</sup>*S. pneumoniae* D39 gene names/annotation (Lanie et al. 2007). <sup>c</sup>Ratio (>1.5 or <-1.5) represents the fold increase/decrease in gene expression in the presence of paracetamol in CDM.

**Table 2**

Number of differentially expressed genes in *S. pneumoniae* D39 wild-type grown in CDM with and without 5 mM paracetamol in CDM. Cut off ratio for gene to be included in the analysis was selected to be 1.5.

| Functional categories  | Total     | Up        | Down      |
|--|-----------|-----------|-----------|
| C: Energy production and conversion                              | 2         | -         | 2         |
| E: Amino acid transport and metabolism                           | 11        | 11        | -         |
| F: Nucleotide transport and metabolism                           | -         | -         | -         |
| G: Carbohydrate transport and metabolism                         | 5         | 3         | 2         |
| H: Coenzyme transport and metabolism                             | 1         | 1         | -         |
| I: Lipid transport and metabolism                                | 8         | 8         | -         |
| J: Translation, ribosomal structure, and biogenesis              | 4         | 2         | 2         |
| K: Transcription   | 6         | 3         | 3         |
| L: Replication, recombination, and repair                        | -         | -         | -         |
| M: Cell wall/membrane/envelope biogenesis                        | 4         | 4         | -         |
| O: Posttranslational modification, protein turnover, chaperones  | 5         | 1         | 4         |
| P: Inorganic ion transport and metabolism                        | 5         | 4         | 1         |
| Q: Secondary metabolites biosynthesis, transport, and catabolism | 2         | 1         | 1         |
| R: General function prediction only                              | 4         | 2         | 2         |
| S: Function unknown  | 5         | 4         | 1         |
| T: Signal transduction mechanisms                                | 2         | 1         | 1         |
| U: Intracellular trafficking, secretion, and vesicular transport | -         | -         | -         |
| V: Defense mechanisms  | 1         | 1         | -         |
| Others   | 9         | 8         | 1         |
| <b>Total number of genes</b>                                     | <b>74</b> | <b>54</b> | <b>20</b> |

result in modifications in the cell membrane that promote cell survival in involvement of paracetamol.

A gene coding for alcohol dehydrogenase (AdhE) was positively regulated during involvement of paracetamol. *S. pneumoniae* D39 strain is susceptible to alcohols which positively regulates AdhE (Luong et al., 2015). Colonization, virulence and hemolytic activity of *S. pneumoniae*, as well as the pro-inflammatory cytokine secretion, inflammation and host cell myeloperoxidase activity were substantially reduced in  $\Delta adhE$  compared to D39 wild-type (Luong et al., 2015), suggesting AdhE to be a pneumococcal virulence factor (Luong et al., 2015). These genes that expressed in numerous ways could be used as potential vaccination candidates or as therapeutic targets.

The expression of the *ciaR-H operon* was altered in the presence of paracetamol. The CiaRH system is a two-component signal transduction system (TCS) and CiaR acts as repressor the competence genes in *S. pneumoniae* (Guenzi et al., 1994). The CiaRH system is vital for providing resistance against cell wall inhibitors and helps maintaining cell integrity (Mascher et al., 2006). Similar findings were observed when pneumococcal transcriptomic response to penicillin was studied (Rogers et al., 2007). These findings imply that stimulation of the CiaRH system and (consequent down-regulation of competence genes) may be a mechanism by which *S. pneumoniae* fights itself against penicillin-induced cell wall damage.

In our gene expression analysis, we see significant upregulation of genes involved in the modulation of misfolded proteins (*hrcA*, *grpE*, *dnaK* and *dnaJ*). This result may be expected as a drug (paracetamol in our case) can induce as protein mistranslation and that is

why the expression of the genes involved in the regulation of misfolded proteins will be enhanced.

### 3.2. PPI network analysis of the differentially expressed genes


PPI networks have been utilized to study health and disease of a certain body and can be very handy for comparison of systems across diverse conditions. The STRING database was used to build PPI networks in order to better understand the connections of differentially expressed genes. As shown in Fig. 1A, the hub genes with node degree greater than or equal to 10 fatty acid biosynthesis and metabolism genes. These genes include *spd-0378*, *acpP*, *fabH*, *fabK*, *fabD*, *fabF*, *fabG*, *accB*, *accC*, *fabZ*, *accD* and *accA*. Another network that was prominent in our analysis was the one consisting of genes involved in the biosynthesis of antibiotics. This network includes *fabD*, *fabG*, *accA*, *accB*, *accC*, *accD*, *spd-1834* (*adhE*), *dapA*, *asd*, *ilvA*, *ilvB*, *ilvC*, *ilvE* and *ilvN*. Both fatty acid biosynthesis and metabolism genes and antibiotics biosynthesis genes' networks have been shown in separate figures (Fig. 1B and 1C, respectively).

### 3.3. KEGG pathways analysis of the differentially regulated genes

These genes pertain to several metabolic pathways including the fatty acid biosynthesis and metabolism pathways (Table 3). The pathway involved in the biosynthesis of antibiotics was also significantly affected under our tested conditions. Moreover, several pathways involved particularly in leucine, valine and isoleucine biosynthesis, pyruvate metabolism, 2-Oxocarboxylic acid metabolism, propanoate and butanoate metabolism, biosynthesis of secondary metabolites and quorum sensing were significantly altered in under our tested conditions (Table 3). These results indicate that paracetamol have diverse effects on several pathways in pneumococcus.

## 4. Discussion

Growing drug resistance is a major challenge in treating pneumococcal throughout the last few decades. Presently, 15–30 % of the pneumococcal strains are categorized as resistant to multiple drugs (Lynch and Zhanel, 2009). Most common drug treatments of pneumococcus involves macrolides,  $\beta$ -lactams, or fluoroquinolones individually or in group (Weiss et al., 2004; Waterer and Rello, 2006). The use of antibiotic combinations broadens the range of bacteria that can be targeted while also increasing efficacy, decreasing the inception and propagation of resistance bacteria. Understanding the response of pneumococci to commonly used drugs may provide novel therapeutic targets and important insights into the adaptive techniques required to interact with the host environment during infection (Leonard and Lalk, 2018). Using paracetamol as a part of combination therapy may be useful. We investigated the relation of *S. pneumoniae* to paracetamol to identify the potential candidates for drugs against pneumococcus. This research will aid in the knowledge of pneumococcal physiology and response to a commonly used drug. To unveil pneumococ-



**Fig. 1.** Protein-protein interaction (PPI) differential network analysis of the pneumococcal transcriptome in response to 5 mM paracetamol in the medium (A), PPI differential network analysis of the fatty acid genes (B) and the antibiotic biosynthesis genes (C).

cal adaptation to a commonly used drug, paracetamol, pneumococci were grown in CDM in the presence of 5 mM paracetamol. The response of strain D39 to paracetamol is complex, comprising a network of genes involved in fatty acid metabolism and biosynthesis, nutrition and waste transport, environmental stress detection, and antibiotic production.

Fatty acid biosynthesis and metabolism gene cluster was significantly downregulated in the presence of paracetamol. The antibacterial effect of fatty acids on the potential of *S. pneumoniae* to induce disease is poorly understood. Fatty acid synthase system type II (FASII) manufactures pneumococcal fatty acids which are needed for the cell membrane (Zhang and Rock, 2008), which is encoded by the *fab* gene cluster. This cluster's transcription is regulated by the MarR-type transcriptional regulator FabT, which suppresses the cluster responsible for *fab*-transcription when fatty acids attach to it (Jerga and Rock, 2009). The pneumococcus can integrate fatty acids that are produced outside (exogenous) into its membrane via the FakA/B system, in complement to *de novo* synthesis by the FASII system (Parsons et al., 2015). Exogenous fatty acids have been shown to reduce pneumococcal colonization

**Table 3**  
List of Significantly Enriched Pathways.

| Pathway name                                 | Observed gene count | FDR      |
|--|---------------------|----------|
| Fatty acid biosynthesis                      | 11/13               | 6.07E-09 |
| Fatty acid metabolism                        | 10/11               | 1.40E-08 |
| Biosynthesis of antibiotics                  | 15/113              | 0.00056  |
| Valine, leucine, and isoleucine biosynthesis | 5/9                 | 0.00096  |
| 2-Oxocarboxylic acid metabolism              | 5/10                | 0.0011   |
| Pyruvate metabolism                          | 6/19                | 0.0015   |
| Propanoate metabolism                        | 5/12                | 0.0016   |
| Butanoate metabolism                         | 4/7                 | 0.0023   |
| Metabolic pathways                           | 26/345              | 0.0023   |
| Pantothenate and CoA biosynthesis            | 4/11                | 0.0071   |
| Biotin metabolism                            | 3/5                 | 0.0088   |
| Biosynthesis of secondary metabolites        | 13/138              | 0.0099   |
| Microbial metabolism in diverse environments | 10/91               | 0.0106   |
| Quorum sensing                               | 7/53                | 0.0168   |
| Biosynthesis of amino acids                  | 8/76                | 0.0299   |
| Monobactam biosynthesis                      | 2/4                 | 0.0465   |
| Nitrogen metabolism                          | 2/4                 | 0.0465   |

Enrichment analysis was performed using the pathway enrichment tool (STRING, version 10.5, <https://www.string-db.org/>). The observed gene count indicates how many genes match the predicted metabolic pathways. FDR, false discovery rate.

in investigations, while the molecular mechanism for this antibacterial activity of free fatty acids is unknown (Bomar et al., 2016). The distinct pneumococcal SpFakB3 can be used due to its special polyunsaturates. To bind the fatty acid carbonyl and normalize the protein, pneumococcal FakB3 uses a distinct hydrogen bond network than other FakBs (Gullett et al., 2019). Deletion of *fakB3* in *S. pneumoniae* strain JMG1 led to reduction in linoleate incorporation from human serum confirms the significance of *fakB3* in this process. FakB3 (*spd-0646*) was one of the genes that was downregulated in our transcriptomic analysis in the presence of paracetamol, which might suggest that *fakB3* can be a very important target for paracetamol and further studies will be needed for deep research. Moreover, the *fab* genes were shown to be downregulated in pneumococcus in the presence of penicillin (Rogers et al., 2007). These genes may share a stress response to cell wall inhibitors since they respond similarly to paracetamol and vancomycin, with some of them potentially important in shielding the cell from their effects.

Iron has a pivotal role in the pathogenesis of *S. pneumoniae*. To successfully support infections and survival, pneumococcus has diversified three transporters named ABC, PiuABC, PiaABC, and PitABC, with lipoproteins PiuA, PiaA, and PitA as proteins that binds to substrate to uptake iron (Yang et al., 2016). In our microarray findings, *piuABC* was downregulated in the existence of paracetamol. These findings were in contrast to a gene expression analysis based on microarray in *S. pneumoniae* which demonstrated that the fluoroquinolone levofloxacin induced a positive regulation of the *piuABC* operon (Ferrández and de la Campa, 2014). They further suggested that upregulation of *piuABC* would cause a rise in intracellular iron, which would then activate the Fenton reaction, resulting in an increase in reactive oxygen species (Ferrández and de la Campa, 2014).

Genes (*glnRA* and *glnPQ*) involved in glutamine synthesis and uptake were among the downregulated ones in the presence of paracetamol. Penicillin therapy increases intracellular glutamine concentrations, according to a recent study (El Khoury et al., 2017). When culture media was supplemented with glutamine, it provided protection against penicillin (El Khoury et al., 2017). The *glnA*-encoded glutamine synthetase catalyzes the conversion of ammonium and glutamate into glutamine, and its chemical inhibition by the L-methionine sulfoximine (inhibitor) has been demonstrated to make *S. pneumoniae* susceptible to penicillin, even in penicillin-resistant clinical isolates (El Khoury et al., 2017).

Therefore, we believe that paracetamol (by altering glutamine genes express) interacts with glutamine metabolism, implying techniques that might be employed in standard treatment or to reverse resistance in future.

A couple of sugar systems *manLMN* and *malPQ* were also expressed in numerous ways in the presence of paracetamol. ManLMN is typically a major glucose transporter that has also the ability of transporting a varying number of other carbohydrate substrates including mannose, fructose, galactose and *N*-acetyl glucosamine (Bidossi et al.,). *manLMN* is repressed by both the CcpA and CiaR, the response regulator of the conserved TCS CiaRH implicated in competence, autolysis and  $\beta$ -lactam resistance (Halfmann et al., 2007; Carvalho et al., 2011). In *S. pneumoniae* D39, inactivation of *manM* encoding the PTS EIIC component, resulted in a mild growth defect in glucose, and more severely reduced growth in *N*-acetyl glucosamine, mannose, and galactose (Bidossi et al.,). In contrast to D39, ManLMN was found to be essential for growth on five non-preferred carbohydrates in TIGR4, and required to induce expression of downstream metabolic genes (Fleming and Camilli, 2016). *malPQ* are the maltose utilization genes and have been shown to be regulated by MalR (Afzal et al., 2015). They code for a maltodextrin phosphorylase and a 4- $\alpha$ -glucanotransferase, respectively. These maltose genes have been demonstrated to be positively regulated during involvement of cellobiose as well (Shafeeq et al., 2013). Our  $\beta$ -galactosidase assays with *PmalP-lacZ* in the presence of cellobiose showed that the activity of *PmalP* was significantly higher in the presence of cellobiose as compared that in glucose (data not shown). This might indicate about the complexity of the role of *malPQ* in the life-style of pneumococcus and differential expression of *malPQ* in the presence of paracetamol corroborates our observation. Moreover, both these *manLMN* and *malPQ* systems have been shown to be differentially expressed in the presence of penicillin and vancomycin in *S. pneumoniae* (Rogers et al., 2007; Haas et al., 2004).

We discovered genes of *S. pneumoniae* that are differently expressed in reaction to paracetamol exposures in our investigation. Several of these genes have been connected to drug resistance or tolerance in the past, demonstrating that their altered expression is part of a stress-protective response in this situation. Such genes could be used as therapeutic targets to improve the effectiveness of paracetamol against this pathogen. Other gene expression changes discovered here could also point to potential paracetamol resistance mechanisms. In this context, more research on these genes is required.

### Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

### Acknowledgements

We thank Prof. Oscar P. Kuipers and Dr. Anne de Jong, University of Groningen, The Netherlands for their help for microarrays experiments. The authors (MFA, SM) express their sincere appreciation to the Researchers Supporting Project Number (RSP2022436) King Saud University, Riyadh, Saudi Arabia.

Proclamations of Ethics.

### Statement of Ethical Guidelines

The manuscript is exempt from ethical committee approval.

### References

- Afzal, M., Shafeeq, S., Manzoor, I., Kuipers, O.P., van Schaik, W., 2015. Maltose-Dependent Transcriptional Regulation of the mal Regulon by MalR in *Streptococcus pneumoniae*. *PLoS ONE* 10 (6). <https://doi.org/10.1371/journal.pone.0127579>.
- Afzal, M., Manzoor, I., Kuipers, O.P., 2015. A Fast and Reliable Pipeline for Bacterial Transcriptome Analysis Case study: Serine-dependent Gene Regulation in *Streptococcus pneumoniae*. *J. Vis. Exp. JoVE*. 98. <https://doi.org/10.3791/52649>.
- A. Bidossi L, Mulas F, Decorosi L, Colomba S, Ricci G, Pozzi J, Deutscher C, Viti M.R, Oggioni E.N, Miyaji A Functional Genomics Approach to Establish the Complement of Carbohydrate Transporters in *Streptococcus pneumoniae* *PLoS ONE* 7 3 e33320.
- Bomar, L., Brugger, S.D., Yost, B.H., Davies, S.S., Lemon, K.P., Huffnagle, G.B., 2016. *Corynebacterium accolens* Releases Antipneumococcal Free Fatty Acids from Human Nostril and Skin Surface Triacylglycerols. *mBio*. 7 (1). <https://doi.org/10.1128/mBio.01725-15>.
- Brockhurst, M.A., Harrison, F., Veening, J.-W., Harrison, E., Blackwell, G., Iqbal, Z., Maclean, C., 2019. Assessing evolutionary risks of resistance for new antimicrobial therapies. *Nat. Ecol. Evol.* 3 (4), 515–517.
- Brown, J.S., Gilliland, S.M., Ruiz-Albert, J., Holden, D.W., 2002. Characterization of Pit, a *Streptococcus pneumoniae* Iron Uptake ABC Transporter. *Infect. Immun.* 70 (8), 4389–4398.
- Carvalho, S.M., Kloosterman, T.G., Kuipers, O.P., Neves, A.R., Horsburgh, M.J., 2011. CcpA ensures optimal metabolic fitness of *Streptococcus pneumoniae*. *PLoS ONE* 6 (10), e26707.
- de Jong, A., Pietersma, H., Cordes, M., Kuipers, O.P., Kok, J., 2012. PePPER: a webserver for prediction of prokaryote promoter elements and regulons. *BMC Genomics* 13, 299. <https://doi.org/10.1186/1471-2164-13-299>.
- El Khoury, J.Y., Boucher, N., Bergeron, M.G., Leprohon, P., Ouellette, M., 2017. Penicillin induces alterations in glutamine metabolism in *Streptococcus pneumoniae*. *Sci. Rep.* 7 (1), 14587. <https://doi.org/10.1038/s41598-017-15035-y>.
- Ferrández, M.J., de la Campa, A.G., 2014. The Fluoroquinolone Levofloxacin Triggers the Transcriptional Activation of Iron Transport Genes That Contribute to Cell Death in *Streptococcus pneumoniae*. *Antimicrob. Agents Chemother.* 58 (1), 247–257. <https://doi.org/10.1128/AAC.01706-13>.
- Fleming, E., Camilli, A., 2016. ManLMN is a glucose transporter and central metabolic regulator in *Streptococcus pneumoniae*. *Mol. Microbiol.* 102 (3), 467–487. <https://doi.org/10.1111/mmi.13473>.
- Guenzi, E., Gasc, A.M., Sicard, M.A., Hakenbeck, R., 1994. A two-component signal-transducing system is involved in competence and penicillin susceptibility in laboratory mutants of *Streptococcus pneumoniae*. *Mol. Microbiol.* 12 (3), 505–515. <https://doi.org/10.1111/j.1365-2958.1994.tb01038.x>.
- Gullett, J.M., Cuyppers, M.G., Frank, M.W., White, S.W., Rock, C.O., 2019. A fatty acid-binding protein of *Streptococcus pneumoniae* facilitates the acquisition of host polyunsaturated fatty acids. *J. Biol. Chem.* 294 (44), 16416–16428. <https://doi.org/10.1074/jbc.RA119.010659>.
- Haas, W., Sublett, J., Kaushal, D., Tuomanen, E.I., 2004. Revisiting the Role of the Pneumococcal *vex-vncRS* Locus in Vancomycin Tolerance. *J. Bacteriol.* 186 (24), 8463–8471.
- Halfmann, A., Kovács, M., Hakenbeck, R., Brückner, R., 2007. Identification of the genes directly controlled by the response regulator CiaR in *Streptococcus pneumoniae*: five out of 15 promoters drive expression of small non-coding RNAs. *Mol. Microbiol.* 66 (1), 110–126.
- Jerga, A., Rock, C.O., 2009. Acyl-Acyl Carrier Protein Regulates Transcription of Fatty Acid Biosynthetic Genes via the FabT Repressor in *Streptococcus pneumoniae*. *J. Biol. Chem.* 284 (23), 15364–15368. <https://doi.org/10.1074/jbc.C109.002410>.
- Kadioglu, A., Weiser, J.N., Paton, J.C., Andrew, P.W., 2008. The role of *Streptococcus pneumoniae* virulence factors in host respiratory colonization and disease. *Nat. Rev. Microbiol.* 6 (4), 288–301.
- Kim, L., McGee, L., Tomczyk, S., Beall, B., 2016. Biological and Epidemiological Features of Antibiotic-Resistant *Streptococcus pneumoniae* in Pre- and Post-Conjugate Vaccine Eras: a United States Perspective. *Clin. Microbiol. Rev.* 29 (3), 525–552. <https://doi.org/10.1128/CMR.00058-15>.
- Kloosterman, T.G., Hendriksen, W.T., Bijlsma, J.J.E., Bootsma, H.J., van Hijum, S.A.F.T., Kok, J., Hermans, P.W.M., Kuipers, O.P., 2006. Regulation of Glutamine and Glutamate Metabolism by GlnR and GlnA in *Streptococcus pneumoniae*. *J. Biol. Chem.* 281 (35), 25097–25109.
- Lee, W.M., 2017. Acetaminophen (APAP) hepatotoxicity—Isn't it time for APAP to go away? *J. Hepatol.* 67 (6), 1324–1331. <https://doi.org/10.1016/j.jhep.2017.07.005>.
- Leonard, A., Lalk, M., 2018. Infection and metabolism – *Streptococcus pneumoniae* metabolism facing the host environment. *Cytokine* 112, 75–86. <https://doi.org/10.1016/j.cyto.2018.07.021>.
- Levine, O.S., Farley, M., Harrison, L.H., Lefkowitz, L., McGeer, A., Schwartz, B., 1999. Risk Factors for Invasive Pneumococcal Disease in Children: A Population-based Case-Control Study in North America. *Pediatrics* 103 (3), e28–e.
- Luong, T.T., Kim, E.-H., Bak, J.P., Nguyen, C.T., Choi, S., Briles, D.E., Pyo, S., Rhee, D.-K., Camilli, A., 2015. Ethanol-induced alcohol dehydrogenase E (AdhE) potentiates pneumolysin in *Streptococcus pneumoniae*. *Infect. Immun.* 83 (1), 108–119.
- Lynch, J., Zhanel, G., 2009. *Streptococcus pneumoniae* : Epidemiology, Risk Factors, and Strategies for Prevention. *Semin Respir Crit Care Med.* 30 (02), 189–209. <https://doi.org/10.1055/s-0029-1202938>.

- Marrakchi, H., Choi, K.H., Rock, C.O., 2002. A new mechanism for anaerobic unsaturated fatty acid formation in *Streptococcus pneumoniae*. *J. Biol. Chem.* 277 (47), 44809–44816. <https://doi.org/10.1074/jbc.M208920200>.
- Mascher, T., Heintz, M., Zähler, D., Merai, M., Hakenbeck, R., 2006. The CiaRH system of *Streptococcus pneumoniae* prevents lysis during stress induced by treatment with cell wall inhibitors and by mutations in *pbp2x* involved in beta-lactam resistance. *J. Bacteriol.* 188 (5), 1959–1968. <https://doi.org/10.1128/JB.188.5.1959-1968.2006>.
- O'Brien, K.L., Wolfson, L.J., Watt, J.P., Henkle, E., Deloria-Knoll, M., McCall, N., Lee, E., Mulholland, K., Levine, O.S., Cherian, T., 2009. Burden of disease caused by *Streptococcus pneumoniae* in children younger than 5 years: global estimates. *Lancet* 374 (9693), 893–902.
- Parsons, J.B., Frank, M.W., Eleveld, M.J., Schalkwijk, J., Broussard, T.C., de Jonge, M.I., Rock, C.O., 2015. A thioesterase bypasses the requirement for exogenous fatty acids in the *plsX* deletion of *S. pneumoniae*: Role of PlsX in *S. pneumoniae* fatty acid metabolism. *Mol. Microbiol.* 96 (1), 28–41.
- Rogers, P.D., Liu, T.T., Barker, K.S., Hilliard, G.M., English, B.K., Thornton, J., Swiatlo, E., McDaniel, L.S., 2007. Gene expression profiling of the response of *Streptococcus pneumoniae* to penicillin. *J. Antimicrob. Chemother.* 59 (4), 616–626.
- Scottish Intercollegiate Guidelines Network. *Control of Pain in Adults with Cancer: A National Clinical Guideline*. Scottish Intercollegiate Guidelines Network; 2008.
- Shafeeq, S., Kuipers, O.P., Kloosterman, T.G., 2013. Cellobiose-mediated gene expression in *Streptococcus pneumoniae*: a repressor function of the novel GntR-type regulator BguR. *PLoS ONE* 8 (2), e57586.
- Szklarczyk, D., Morris, J.H., Cook, H., Kuhn, M., Wyder, S., Simonovic, M., Santos, A., Doncheva, N.T., Roth, A., Bork, P., Jensen, L.J., von, C., Mering, 2017. The STRING database in 2017: quality-controlled protein–protein association networks, made broadly accessible. *Nucleic Acids Res.* 45 (D1), D362–D368.
- Torné, A.N., Dias, J.G., Quinten, C., Hrubá, F., Busana, M.C., Lopalco, P.L., Gauci, A.J.A., Pastore-Celentano, L., 2014. European enhanced surveillance of invasive pneumococcal disease in 2010: Data from 26 European countries in the post-heptavalent conjugate vaccine era. *Vaccine* 32 (29), 3644–3650.
- van Hijum, S.A., de Jong, A., Baerends, R.J.S., Karsens, H.A., Kramer, N.E., Larsen, R., den Hengst, C.D., Albers, C.J., Kok, J., Kuipers, O.P., 2005. A generally applicable validation scheme for the assessment of factors involved in reproducibility and quality of DNA-microarray data. *BMC Genomics* 6 (1).
- van Hijum SAFT, Garcia de la Nava J, Trelles O, Kok J, Kuipers OP. MicroPreP: a cDNA microarray data pre-processing framework. *ApplBioinformatics*. 2003;2(1175-5636; 4):241-244.
- Waterer, G., Rello, J., 2006. Choosing the right combination therapy in severe community-acquired pneumonia. *Crit. Care* 10 (1), 115. <https://doi.org/10.1186/cc3976>.
- Weiss, K., Low, D.E., Cortes, L., Beaupre, A., Gauthier, R., Gregoire, P., Legare, M., Neveu, F., Thibert, D., Tremblay, C., 2004. Clinical Characteristics at Initial Presentation and Impact of Dual Therapy on the Outcome of Bacteremic *Streptococcus pneumoniae* Pneumonia in Adults. *Can Respir J.* 11 (8), 589–593.
- Yang, X.-Y., He, K.e., Du, G., Wu, X., Yu, G., Pan, Y., Zhang, G., Sun, X., He, Q.-Y., 2016. Integrated Translatomics with Proteomics to Identify Novel Iron-Transporting Proteins in *Streptococcus pneumoniae*. *Front. Microbiol.* 7. <https://doi.org/10.3389/fmicb.2016.00078>.
- Zhang, Y.M., Rock, C.O., 2008. Membrane lipid homeostasis in bacteria. *Nat. Rev. Microbiol.* 6 (3), 222–233. <https://doi.org/10.1038/nrmicro1839>.